Literature DB >> 3235524

Simultaneous determination of ofloxacin, fenbufen and felbinac in rat plasma by high-performance liquid chromatography.

Y Katagiri1, K Naora, N Ichikawa, M Hayashibara, K Iwamoto.   

Abstract

Ofloxacin, fenbufen and its active metabolite, felbinac, were simultaneously extracted from 50 microliters of rat plasma and analysed by high-performance liquid chromatography on a reversed-phase column. Quantitative and reproducible determinations were possible for ofloxacin, fenbufen and felbinac over the concentration ranges 0.15-40, 0.3-80 and 0.45-45 micrograms/ml, respectively. The detection limits for all the drugs were lower than those reported previously. The recovery of ofloxacin, fenbufen and felbinac added to plasma was nearly 100% with a coefficient of variation of less than 3.0%. This method was found to be applicable to pharmacokinetic studies of each drug after the concomitant administration of ofloxacin and fenbufen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3235524     DOI: 10.1016/s0378-4347(00)83076-5

Source DB:  PubMed          Journal:  J Chromatogr


  4 in total

1.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats.

Authors:  E F Foote; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  The effect of food on the interaction of ofloxacin with sucralfate in healthy volunteers.

Authors:  J Kawakami; T Matsuse; H Kotaki; T Seino; Y Fukuchi; H Orimo; Y Sawada; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.